<p>Clinical efficacy and safety of rituximab in lupus nephritis</p>

Zhiqing Zhong, Hongyan Li, Hongzhen Zhong, Tian‐Biao ZhouDrug 2019 · DOI

Abstract

RTX is a promising therapy for the treatment of LN due to significant clinical efficacy and a favorable safety profile. In future studies, larger study populations and longer-term time points may identify additional important patient-centered outcomes.
BibTeX
@inproceedings{zhong2019lt,
  author = {Zhiqing Zhong and Hongyan Li and Hongzhen Zhong and Tian‐Biao Zhou},
  title = {{\<p\>Clinical efficacy and safety of rituximab in lupus nephritis\</p\>}},
  booktitle = {Drug},
  year = {2019},
  doi = {10.2147/dddt.s195113},
}

Loading related content...

Figure